Literature DB >> 24813443

Distinct nucleic acid interaction properties of HIV-1 nucleocapsid protein precursor NCp15 explain reduced viral infectivity.

Wei Wang1, Nada Naiyer1, Mithun Mitra1, Jialin Li2, Mark C Williams2, Ioulia Rouzina3, Robert J Gorelick4, Zhengrong Wu1, Karin Musier-Forsyth5.   

Abstract

During human immunodeficiency virus type 1 (HIV-1) maturation, three different forms of nucleocapsid (NC) protein-NCp15 (p9 + p6), NCp9 (p7 + SP2) and NCp7-appear successively. A mutant virus expressing NCp15 shows greatly reduced infectivity. Mature NCp7 is a chaperone protein that facilitates remodeling of nucleic acids (NAs) during reverse transcription. To understand the strict requirement for NCp15 processing, we compared the chaperone function of the three forms of NC. NCp15 anneals tRNA to the primer-binding site at a similar rate as NCp7, whereas NCp9 is the most efficient annealing protein. Assays to measure NA destabilization show a similar trend. Dynamic light scattering studies reveal that NCp15 forms much smaller aggregates relative to those formed by NCp7 and NCp9. Nuclear magnetic resonance studies suggest that the acidic p6 domain of HIV-1 NCp15 folds back and interacts with the basic zinc fingers. Neutralizing the acidic residues in p6 improves the annealing and aggregation activity of NCp15 to the level of NCp9 and increases the protein-NA aggregate size. Slower NCp15 dissociation kinetics is observed by single-molecule DNA stretching, consistent with the formation of electrostatic inter-protein contacts, which likely contribute to the distinct aggregate morphology, irregular HIV-1 core formation and non-infectious virus.
© The Author(s) 2014. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24813443      PMCID: PMC4066767          DOI: 10.1093/nar/gku335

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  116 in total

1.  Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease.

Authors:  N Sheng; S C Pettit; R J Tritch; D H Ozturk; M M Rayner; R Swanstrom; S Erickson-Viitanen
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  Targeting protein-protein and protein-nucleic acid interactions for anti-HIV therapy.

Authors:  Mattia Mori; Fabrizio Manetti; Maurizio Botta
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

3.  C-terminal domain modulates the nucleic acid chaperone activity of human T-cell leukemia virus type 1 nucleocapsid protein via an electrostatic mechanism.

Authors:  Dominic F Qualley; Kristen M Stewart-Maynard; Fei Wang; Mithun Mitra; Robert J Gorelick; Ioulia Rouzina; Mark C Williams; Karin Musier-Forsyth
Journal:  J Biol Chem       Date:  2009-11-03       Impact factor: 5.157

Review 4.  The choreography of HIV-1 proteolytic processing and virion assembly.

Authors:  Sook-Kyung Lee; Marc Potempa; Ronald Swanstrom
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

5.  Use of terbium as a probe of tRNA tertiary structure and folding.

Authors:  M R Hargittai; K Musier-Forsyth
Journal:  RNA       Date:  2000-11       Impact factor: 4.942

6.  Elucidation of New Binding Interactions with the Tumor Susceptibility Gene 101 (Tsg101) Protein Using Modified HIV-1 Gag-p6 Derived Peptide Ligands.

Authors:  Sung-Eun Kim; Fa Liu; Young Jun Im; Andrew G Stephen; Matthew J Fivash; Abdul A Waheed; Eric O Freed; Robert J Fisher; James H Hurley; Terrence R Burke
Journal:  ACS Med Chem Lett       Date:  2011-05-12       Impact factor: 4.345

7.  HIV-1 nucleocapsid protein induces "maturation" of dimeric retroviral RNA in vitro.

Authors:  Y X Feng; T D Copeland; L E Henderson; R J Gorelick; W J Bosche; J G Levin; A Rein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

8.  1H, 13C, and 15N NMR backbone assignments and secondary structure of human interferon-gamma.

Authors:  S Grzesiek; H Döbeli; R Gentz; G Garotta; A M Labhardt; A Bax
Journal:  Biochemistry       Date:  1992-09-08       Impact factor: 3.162

9.  Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1.

Authors:  Lori V Coren; James A Thomas; Elena Chertova; Raymond C Sowder; Tracy D Gagliardi; Robert J Gorelick; David E Ott
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

10.  Mechanistic insights into the kinetics of HIV-1 nucleocapsid protein-facilitated tRNA annealing to the primer binding site.

Authors:  Michele R S Hargittai; Robert J Gorelick; Ioulia Rouzina; Karin Musier-Forsyth
Journal:  J Mol Biol       Date:  2004-04-02       Impact factor: 5.469

View more
  21 in total

1.  Selection of fully processed HIV-1 nucleocapsid protein is required for optimal nucleic acid chaperone activity in reverse transcription.

Authors:  Tiyun Wu; Robert J Gorelick; Judith G Levin
Journal:  Virus Res       Date:  2014-06-20       Impact factor: 3.303

2.  The C-terminal p6 domain of the HIV-1 Pr55Gag precursor is required for specific binding to the genomic RNA.

Authors:  Noé Dubois; Keith K Khoo; Shannon Ghossein; Tanja Seissler; Philippe Wolff; William J McKinstry; Johnson Mak; Jean-Christophe Paillart; Roland Marquet; Serena Bernacchi
Journal:  RNA Biol       Date:  2018-08-04       Impact factor: 4.652

3.  Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.

Authors:  Angelica N Martins; Abdul A Waheed; Sherimay D Ablan; Wei Huang; Alicia Newton; Christos J Petropoulos; Rodrigo D M Brindeiro; Eric O Freed
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

4.  Solution Conformation of Bovine Leukemia Virus Gag Suggests an Elongated Structure.

Authors:  Dominic F Qualley; Sarah E Cooper; James L Ross; Erik D Olson; William A Cantara; Karin Musier-Forsyth
Journal:  J Mol Biol       Date:  2019-02-04       Impact factor: 5.469

5.  Nucleocapsid Protein Precursors NCp9 and NCp15 Suppress ATP-Mediated Rescue of AZT-Terminated Primers by HIV-1 Reverse Transcriptase.

Authors:  Moisés A Árquez; Samara Martín-Alonso; Robert J Gorelick; Walter A Scott; Antonio J Acosta-Hoyos; Luis Menéndez-Arias
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

6.  Single aromatic residue location alters nucleic acid binding and chaperone function of FIV nucleocapsid protein.

Authors:  Hao Wu; Wei Wang; Nada Naiyer; Eric Fichtenbaum; Dominic F Qualley; Micah J McCauley; Robert J Gorelick; Ioulia Rouzina; Karin Musier-Forsyth; Mark C Williams
Journal:  Virus Res       Date:  2014-06-07       Impact factor: 3.303

7.  Insights into the mechanisms of RNA secondary structure destabilization by the HIV-1 nucleocapsid protein.

Authors:  Anissa Belfetmi; Loussiné Zargarian; Carine Tisné; Dona Sleiman; Nelly Morellet; Ewen Lescop; Ouerdia Maskri; Brigitte René; Yves Mély; Philippe Fossé; Olivier Mauffret
Journal:  RNA       Date:  2016-01-29       Impact factor: 4.942

8.  Glutamic Acid Residues in HIV-1 p6 Regulate Virus Budding and Membrane Association of Gag.

Authors:  Melanie Friedrich; Christian Setz; Friedrich Hahn; Alina Matthaei; Kirsten Fraedrich; Pia Rauch; Petra Henklein; Maximilian Traxdorf; Torgils Fossen; Ulrich Schubert
Journal:  Viruses       Date:  2016-04-25       Impact factor: 5.048

9.  Characterization of the interaction between the HIV-1 Gag structural polyprotein and the cellular ribosomal protein L7 and its implication in viral nucleic acid remodeling.

Authors:  Hala El Mekdad; Emmanuel Boutant; Hassan Karnib; Marina E Biedma; Kamal Kant Sharma; Iuliia Malytska; Géraldine Laumond; Marion Roy; Eléonore Réal; Jean-Christophe Paillart; Christiane Moog; Jean Luc Darlix; Yves Mély; Hugues de Rocquigny
Journal:  Retrovirology       Date:  2016-08-11       Impact factor: 4.602

Review 10.  The Life-Cycle of the HIV-1 Gag-RNA Complex.

Authors:  Elodie Mailler; Serena Bernacchi; Roland Marquet; Jean-Christophe Paillart; Valérie Vivet-Boudou; Redmond P Smyth
Journal:  Viruses       Date:  2016-09-10       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.